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Acute respiratory distress syndrome (ARDS) is defined as an acute-onset, progressive, hypoxic condition with
radiographic bilateral lung infiltration, which develops after several diseases or injuries, and is not derived from
hydrostatic pulmonary edema. One specific pathological finding of ARDS is diffuse alveolar damage. In 2012, in
an effort to increase diagnostic specificity, a revised definition of ARDS was published in JAMA. However, no new
parameters or biomarkers were adopted by the revised definition. Discriminating between ARDS and other similar
diseases is critically important; however, only a few biomarkers are currently available for diagnostic purposes.
Furthermore, predicting the severity, response to therapy, or outcome of the illness is also important for developing
treatment strategies for each patient. However, the PaO2/FIO2 ratio is currently the sole clinical parameter used
for this purpose. In parallel with progress in understanding the pathophysiology of ARDS, various humoral factors
induced by inflammation and molecules derived from activated cells or injured tissues have been shown as
potential biomarkers that may be applied in clinical practice. In this review, the current understanding of the basic
pathophysiology of ARDS and associated candidate biomarkers will be discussed.
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Acute respiratory distress syndrome (ARDS) is defined
as an acute-onset, progressive, hypoxic condition charac-
terized by bilateral lung infiltration on chest X-ray or
computed tomography [1]. ARDS develops quickly after
several conditions, traumas, or insults. However, it needs
to be confirmed that the condition does not result from
heart or renal failure or overhydration. Diffuse alveolar
damage (DAD) is designated as a specific pathological
finding for ARDS. For more than two decades, the defin-
ition set forth by the American-European Consensus Con-
ference (AECC) has been used for the clinical diagnosis of
ARDS [2], and a newer definition with better specificity
has long been awaited. In 2011, a draft of a revised defin-
ition was presented at the 24th Annual Congress of the
European Society of Intensive Care Medicine in Berlin,
and its final version was published in JAMA in May 2012
[3]. In the revised Berlin definition, the term ARDS was
redefined as a broader concept including a milder condi-
tion of lung injury; therefore, it became equivalent toCorrespondence: fujishim@z6.keio.jp
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unless otherwise stated.acute lung injury (ALI), which was the previous AECC
definition.
The revised ARDS definition was significantly improved
by the inclusion of timing, underlying conditions, and the
mandated determination of the PaO2/FIO2 ratio under
positive airway pressure. However, no new parameters or
biomarkers were adopted. In this review, the current
understanding of the basic ARDS pathophysiology and
associated candidate biomarkers will be discussed.Review
Regulation of vascular permeability
The essential pathophysiology of ARDS includes increased
pulmonary microvascular permeability. The process of
water passage from the capillaries to the alveoli is pre-
sented with several physical barriers, including endothelial
and epithelial cell layers, the basement membrane, and
the extracellular matrix. Among these barriers, water pas-
sage (permeability) across endothelial and epithelial cell
layers is actively regulated. Increased vascular permeability
in ARDS is the result of several independent mechanisms.
First, tissue injury and the resultant destruction of the pul-
monary microvascular architecture contribute to a direct. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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alveoli. In addition, endothelial and epithelial permeability
is dynamically regulated by a set of inter- and intracellular
molecules, the dysregulation of which may also induce
increased vascular permeability. In order to protect the
lungs from pulmonary edema, the pulmonary lymphatic
system and epithelial water channels play important roles
in pumping water out of extravascular space. However,
when vascular leakage surpasses the capacity of these
compensating systems, clinical pulmonary edema deve-
lops. There are multiple mechanisms by which vascular
permeability is regulated. Sphingosine-1 phosphate (S1P)
binds to its receptor, S1P1, and regulates vascular perme-
ability through non-muscle myosin light chain kinase
(nmMLCK) and the Rho family GTPase pathway [4]. In
addition, angiopoietin-1 (Ang-1) binds to its receptor,
tie-2, to stabilize the vasculature through the activa-
tion of Syx and Rho A [5]. In contrast, angiopoietin-2
(Ang-2) is produced by activated endothelial cells and
competes with Ang1 for tie2 binding to destabilize
vascular junctional formation [6]. The dysregulation
of any of these mechanisms may lead to a change in vas-
cular permeability; therefore, these factors may represent
potential biomarkers for ARDS.
The innate immune system and inflammation
Acute inflammation of and neutrophil accumulation in
the lungs are commonly observed in both patients with
ARDS and animal models of the disease. Extensive re-
search has revealed the pathogenic roles of neutrophil-
mediated acute inflammation in ARDS development [7].
Neutrophils release cytotoxic molecules, including granu-
lar enzymes, reactive oxygen metabolites, bioactive lipids,
and cytokines, and induce the formation of neutrophil
extracellular traps (NETs) [8]. In addition to causing tissue
necrosis, these cytotoxic molecules induce apoptosis and
autophagy, each of which causes tissue injury and cell
death, which are characteristic of ARDS [9].
Numerous proinflammatory cytokines play major roles
in acute inflammation and the development of inflamma-
tory lung diseases, including ARDS. Among these, tumor
necrosis factor alpha (TNFα) and interleukin 1beta (IL-1β)
can induce ALI when administered to animals, and their
levels are also elevated in the lungs of ARDS patients.
Therefore, they are thought to be key pathogenic cyto-
kines in ARDS. In addition, a neutrophil chemotactic che-
mokine, interleukin 8 (IL-8, CXCL8), is important because
its neutralizing antibody was protective against the devel-
opment of ALI in animal models, and IL-8 levels are
elevated in the lungs of ARDS patients [10]. Additional
cytokines and chemokines are involved in the develop-
ment of ARDS, including IL-18 and IL-33, both of which,
like IL-1β, are regulated by the inflammasome/caspase-1
pathway [11,12]. These cytokines may represent goodtargets for antimediator therapy for ARDS as well as
become potential biomarkers of ARDS.
Recently, pattern recognition receptors (PRRs) were dem-
onstrated to play a key role in innate immunity [13]. PRRs
are cell-surface or cytosolic proteins expressed by innate
immune cells, and each is activated by a specific molecule
(s). PRR ligands are divided into two categories, namely,
pathogen-associated molecular patterns (PAMPs) and
damage (danger)-associated molecular patterns (DAMPs).
PAMPS are extrinsic molecules derived from various
microorganisms, while DAMPs are intrinsic molecules de-
rived from injured cells or extracellular molecules. When
these PRRs are activated, nuclear factor (NF)-κB translo-
cates to the nucleus, predominantly through a myeloid
differentiation primary response gene 88 (MyD88)-depen-
dent mechanism. Activation of PRRs also leads to the
transcription of proinflammatory cytokines such as TNFα,
IL-1β, and IL-8. Table 1 lists the major PRRs and their
counterpart PAMPs and DAMPs.
Infection, including severe sepsis and pneumonia, is
the leading predisposing factor for ARDS. In this regard,
the pathogenic roles of lipopolysaccharide (LPS) have
been thoroughly examined. Because other PAMPs can
induce proinflammatory reactions, it is reasonable to
speculate that they also play important roles in the
development and progression of ARDS. In addition,
because tissue destruction (i.e., multiple trauma and burn
injuries) is a major predisposing factor for ARDS, we can
speculate that DAMPs play critical roles in its onset and/
or progression. The high-mobility group box 1 protein
(HMGB1) was one of the earliest discovered nuclear bind-
ing proteins demonstrated to function as a DAMP [14].
This protein not only leaks from damaged cells, but its
production is also induced in activated dendritic cells and
macrophages. HMGB1 can potently induce inflammation
through its interaction with multiple receptors, including
the receptor for advanced glycation end products (RAGE),
toll-like receptor 2 (TLR2), and toll-like receptor 4 (TLR4).
Initially, a pathogenic role of HMGB1 was reported in
association with sepsis; subsequently, its involvement in
ARDS was also revealed [15,16]. Histone, another nuclear
binding protein, is released into the circulation after
trauma and can induce inflammation and ALI in animal
models [17]. Further, mitochondrial DNA can induce the
production of IL-8 and thus may play a role in ARDS as a
DAMP [18]. At present, however, little is known of the
pathogenic roles of PRRs, PAMPs, and DAMPs in
ARDS, and their involvement needs to be clarified in fu-
ture studies.
Currently available biomarkers in clinical practice
Differentiating similar diseases or conditions from ARDS
remains to be a matter of great importance. Currently,
only a few biomarkers are clinically available for this
Table 1 Representative pattern recognition receptors (PRRs) and their ligands
Family Member PAMPs DAMPs
TLR TLR1 Lipopeptides, lipoarabinomannan Serum amyloid A protein
TLR2 Lipopeptides, LTA, lipoarabinomannan, mannan,
virus structural protein, zymosan, β-glucan
HMGB1, serum amyloid A protein
TLR3 dsRNA
TLR4 LPS, virus structural protein HMGB1, HSP60, HSP70, S100, HA, fatty acid
TLR5 Flagellin
TLR6 Lipopeptides, zymosan, β-glucan HA
TLR7 ssRNA
TLR8 ssRNA
TLR9 CpG-DNA Histone, mitochondrial DNA, self-DNA-
containing immune complexes
NLR NOD1 DAP-type PGN
NOD2 MDP
NLRC4 Flagellin, bacterial secretion systems
NLRP3 Pore-forming toxins, MDP Nucleic acid, ATP, uric acid, HA, silica
RLR RIG-I dsRNA Immunocomplex of snRNPs
Immunoglobulin superfamily RAGE AGEs, HMGB-1, S100B, transthyretin,
amyloid-β peptide, Mac-1 integrin
PRRs pattern recognition receptors, PAMPs pathogen-associated molecular patterns, DAMPs damage (danger)-associated molecular patterns, TLR toll-like receptor,
LTA lipoteichoic acid, HMGB-1 high-mobility group box 1, LPS lipopolysaccharide, HSP heat shock protein, HA hyaluronic acid, NLR nucleotide-binding
oligomerization domain (NOD)-like receptor, DAP-type PGN diaminopimelic acid containing peptidoglycan, MDP muramyl dipeptide, NLRC4 NLR family CARD
domain containing 4, NLRP3 NLR family pyrin domain containing 3, ATP adenosine triphosphate, RLR retinoic acid-inducible gene-I (RIG-I)-like receptor, RAGEs
receptor for advanced glycation end products, AGEs advanced glycation end products.
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used for differentiation between ARDS and hydrostatic
pulmonary edema, although its usefulness remains con-
troversial [19,20]. Procalcitonin is increased in bacterial
infection, but not in viral or fungal infection; it may be
useful for discriminating between bacterial pneumonia
and ARDS. However, because the sensitivity of procalcito-
nin is as high as 70% for bacterial pneumonia and because
bacterial pneumonia and sepsis are common predisposing
conditions for ARDS, its utility is limited [21].
Predicting the severity of illness is also important to
develop a specific diagnostic strategy for each patient
with ARDS, but the PaO2/FIO2 ratio is the sole clinical
parameter used for this purpose. The importance of
biomarkers is underscored by the fact that they can also
be utilized to predict response to therapy and prognosis.
However, no ARDS-specific biomarkers are currently
available for these purposes.
Humoral factors as biomarkers of ARDS
As discussed above, various humoral factors have been
identified as candidate biomarkers of ARDS (Table 2).
Among the proinflammatory cytokines, TNFα, IL-1β,
interleukin 6 (IL-6), and IL-8 are elevated in the bron-
choalveolar lavage fluid (BALF) of ARDS patients, and
their levels were reportedly higher in non-survivors than
in survivors [22]. We previously showed that IL-8 levelsin BALF were higher in patients with ARDS and inhal-
ation injury [10,23]. These levels were also able to predict
the degree of lung oxygenation impairment in inhalation
injury. Recent secondary analysis of the ARDS Clinical
Network's (ARDSnet) activated protein C study, where
various candidate biomarkers of ARDS were assessed,
showed that plasma plasminogen activator inhibitor 1
(PAI-1) and IL-6 were correlated with the oxygenation
index (mean airway pressure × FIO2/PaO2). Furthermore,
ventilator-free days were significantly shorter in patients
with higher levels of IL-6, IL-8, and thrombomodulin,
which were associated with poor patient outcomes [24].
Among these three molecules, the usefulness of IL-8 in
predicting the outcome of ARDS was confirmed by several
additional studies [25,26]. A recent report from Harvard
demonstrated that IL-18 is a new ARDS biomarker [12].
This study was independently performed by three affili-
ated hospitals and showed a consistent increase in plasma
IL-18 levels in ARDS patients, while mortality was in-
creased in direct proportion to plasma IL-18 levels.
Several growth factors have been determined to be
candidate biomarkers of ARDS. In this regard, the lung
levels of vascular endothelial growth factor (VEGF) and
keratinocyte growth factor (KGF) were shown to cor-
relate with the severity of illness and reflect patient
outcome [27,28]. Furthermore, secondary analysis of the
ARDSnet's Fluid and Catheter Treatment (FACT) study
Table 2 Biomarkers of ARDS
Name Change in ARDS Clinical prediction
Humoral mediators
Cytokines, growth factors
TNFα BALF↑ Poor outcome
IL-1β BALF↑ Poor outcome
IL-2 Blood↑ Development
IL-4 Blood↑ Development
IL-6 Blood↑, BALF↑ Poor outcome
IL-8 Blood↑, BALF↑ Development and severity (BALF), poor outcome
IL-18 Blood↑ Poor outcome
VEGF ELF↑ Better outcome
KGF BALF↑ Poor outcome
GDF-15 Blood↑ Poor outcome
Ang-2 Blood↑ Development, poor outcome
Neutrophil elastase Blood↑ Development and severity
Leptin BALF↑ Poor outcome
Coagulation/fibrinolysis factors
PAI-1 Blood↑ Poor outcome
Thrombomodulin Blood↑ Poor outcome
von Willebrand factor Blood↑ Development
Protein C Blood↓ Poor outcome
Substances released from injured or activated tissues
DAMPs
HMGB-1 Blood↑ Poor outcome
DNA BALF↑ Poor outcome
Endothelial cells
Soluble P-selectin Blood↑ Poor outcome
Soluble ICAM-1 Blood↑ Poor outcome
Epithelial cells
Soluble RAGE Blood↑ Poor outcome
SP-B Blood↑ Development
SP-D Blood↑ Poor outcome
CC-16 Blood↑ Poor outcome
Laminin γ2 ELF↑ Poor outcome
KL-6 Blood↑, BALF↑ Poor outcome
BALF bronchoalveolar lavage fluid, ELF epithelial lining fluid, TNFα tumor necrosis factor alpha, IL interleukin, VEGF vascular endothelial growth factor, KGF
keratinocyte growth factor, GDF-15 growth differentiation factor-15, Ang-2 angiopoietin-2, PAI-1 plasminogen activator inhibitor 1, DAMPs damage (danger)-associated
molecular patterns, HMGB-1 high-mobility group box 1, ICAM-1 intercellular adhesion molecule 1, RAGE receptor for advanced glycation end products, SP surfactant
protein, CC-16 Clara cell specific protein 16, KL-6 Krebs von den Lungen-6.
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factor-15 (GDF-15) were increased in proportion to
60-day mortality [29]. Another recent study showed
that Ang-2, a competitor of Ang-1 and a regulator of
vascular permeability (as mentioned earlier), could predict
the prognosis of ARDS [30].
As described, among inflammatory cells, neutrophils
play dominant roles in inducing ARDS through the releaseof various cytotoxic substances and mediators, including
granular enzymes, reactive oxygen species, bioactive lipids,
cytokines, and NETs. Therefore, these neutrophil-derived
molecules can be candidate biomarkers of ARDS. Neutro-
phil elastase, a major granular enzyme with potent non-
specific tissue destruction activity, forms a complex
with alpha 1-antitrypsin (NE-AT) soon after release
from activated neutrophils. We have previously shown
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ARDS patients and were significantly higher in a subgroup
of patients with clinical deterioration after admission than
in a subgroup without deterioration [31].
Leptin, a hormone involved in the regulation of energy
intake and expenditure, was also shown to contribute to
ARDS development. Epidemiological data demonstrated
the low incidence of ARDS among patients with diabetes
mellitus; however, the reason for this is unknown [32,33].
Recently, a decrease in leptin levels in these patients was
shown as a potential key mechanism underlying this
epidemiological finding. In an animal experiment, leptin
induced the expression of transforming growth factor beta
(TGF-β) and the production of collagen types I and II in
the presence of TGF-β, and leptin-deficient mice were
resistant to the development of ALI [34]. Furthermore, in
non-obese patients with ARDS, leptin levels in BALF
correlated with TGF-β levels. The duration of artificial ven-
tilation and ICU stay was significantly longer in a subgroup
of ARDS patients with higher leptin levels in BALF than in
those with lower leptin levels in BALF [34]. These results
suggest that leptin can be a candidate biomarker of ARDS.
Substances derived from activated cells or injured tissues
as biomarkers of ARDS
Substances derived from activated cells or injured tissues
can also reflect the degree of inflammation or tissue
injury and, consequently, the severity of ARDS. In
addition to the earlier discussed pathogenic role of
HMGB1 in ARDS, it was shown to be a candidate bio-
marker of ARDS, along with soluble RAGE [15]. Excessive
formation and ineffective clearance of neutrophil extracel-
lular trap in alveolar space would be responsible for the
pathogenesis of ARDS. The increase in DNA decorated
with proteases and histone in BALF was observed in cystic
fibrosis [35] and acute inhalation injuries [36]. Thus, DNA
in BALF could also become the candidate as biomarker
for ARDS. Similarly, histone may be useful as an ARDS
biomarker in patients with lungs subjected to multiple
trauma [17]. As the roles of DAMPs in the pathophy-
siology of ARDS are revealed, their utility as biomarkers
will also be clarified.
Among endothelial cell-derived molecules, plasma levels
of soluble P-selectin and soluble intercellular adhesion
molecule (sICAM-1) were reported as candidate bio-
markers. The potential of sICAM-1 was demonstrated
by multicenter studies [37,38]. Additional epithelial cell-
derived molecules that represent candidate ARDS bio-
markers include sialylated carbohydrate antigen Krebs von
den Lungen-6 (KL-6, a fragment of MUC1 mucin), surfac-
tant protein B (SP-B) [39], surfactant protein D (SP-D)
[25,26,40], Clara cell protein CC-16 [41], and the gamma-
2 chain of laminin-5 (an extracellular matrix protein with
cell adhesive properties) [42].In 2014, an article that focused on a new meta-analysis
of plasma biomarkers for ARDS was published [43]. The
authors analyzed 54 studies and found that KL-6, lactate
dehydrogenase, soluble RAGE, and von Willebrand fac-
tor are strongly associated with ARDS diagnosis in the
at-risk population. For outcome prediction, they found
that IL-4, IL-2, Ang-2, and KL-6 were most strongly
associated with mortality from ARDS.Conclusions
In parallel with progress in the understanding of ARDS
pathophysiology, several molecules have been shown to
be candidate biomarkers of this disease, with the clinical
usefulness of some being confirmed by large-scale or
multicenter studies. However, none of these candidates
have been clinically applied for diagnosis or prediction
of disease severity, response to therapy, and prognosis in
patients with ARDS. Future studies, along with a search
for new biomarker candidates, need to determine the
potential application(s) of each candidate discussed here.
This will lead to improved diagnosis and treatment strat-
egies for patients with ARDS.
Competing interests
The author declares that he has no competing interest.
Received: 31 March 2014 Accepted: 24 April 2014
Published: 7 May 2014
References
1. Koh Y: Update in acute respiratory distress syndrome. J Intensive Care
2014, 2:2.
2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall
JR, Morris A, Spragg R: The American-European Consensus Conference on
ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial
coordination. Am J Respir Crit Care Med 1994, 149(3 Pt 1):818–824.
3. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell
E, Fan E, Camporota L, Slutsky AS: Acute respiratory distress syndrome:
the Berlin definition. JAMA 2012, 307(23):2526–33.
4. Garcia JG: Concepts in microvascular endothelial barrier regulation in
health and disease. Microvasc Res 2009, 77(1):1–3.
5. Wang L, Dudek SM: Regulation of vascular permeability by sphingosine
1-phosphate. Microvasc Res 2009, 77(1):39–45.
6. Eklund L, Saharinen P: Angiopoietin signaling in the vasculature.
Exp Cell Res 2013, 319(9):1271–80.
7. Fujishima S, Aikawa N: Neutrophil-mediated tissue injury and its
modulation. Intensive Care Med 1995, 21(3):277–85.
8. Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew AA, Phoon MC, Van
Rooijen N, Chow VT: Excessive neutrophils and neutrophil extracellular
traps contribute to acute lung injury of influenza pneumonitis.
Am J Pathol 2011, 179(1):199–210.
9. Martin TR: Interactions between mechanical and biological processes in
acute lung injury. Proc Am Thorac Soc 2008, 5(3):291–6.
10. Fujishima S: A prominent role of IL-8 in inflammatory lung diseases and
multiple organ dysfunction syndrome. Jap J Inflam 1998, 18(6):433–7.
11. Martinez-Gonzalez I, Roca O, Masclans JR, Moreno R, Salcedo MT,
Baekelandt V, Cruz MJ, Rello J, Aran JM: Human mesenchymal stem cells
overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate
endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 2013,
49(4):552–62.
12. Dolinay T, Kim YS, Howrylak J, Hunninghake GM, An CH, Fredenburgh L,
Massaro AF, Rogers A, Gazourian L, Nakahira K, Haspel JA, Landazury R,
Eppanapally S, Christie JD, Meyer NJ, Ware LB, Christiani DC, Ryter SW, Baron
Fujishima Journal of Intensive Care 2014, 2:32 Page 6 of 6
http://www.jintensivecare.com/content/2/1/32RM, Choi AM: Inflammasome-regulated cytokines are critical mediators of
acute lung injury. Am J Respir Crit Care Med 2012, 185(11):1225–34.
13. Opitz B, Van Laak V, Eitel J, Suttorp N: Innate immune recognition in
infectious and noninfectious diseases of the lung. Am J Respir Crit Care
Med 2010, 181(12):1294–309.
14. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J,
Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E,
Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ:
HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999,
285(5425):248–51.
15. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S:
Increased levels of soluble receptor for advanced glycation end
products (sRAGE) and high mobility group box 1 (HMGB1) are
associated with death in patients with acute respiratory distress
syndrome. Clin Biochem 2011, 44(8–9):601–4.
16. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M,
Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H,
Ishizaka A: Contributions of high mobility group box protein in
experimental and clinical acute lung injury. Am J Respir Crit Care Med
2004, 170(12):1310–6.
17. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, Wang SS, Brohi K,
Kipar A, Yu W, Wang G, Toh CH: Circulating histones are mediators of
trauma-associated lung injury. Am J Respir Crit Care Med 2013,
187(2):160–9.
18. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K,
Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory
responses to injury. Nature 2010, 464(7285):104–7.
19. Levitt JE, Vinayak AG, Gehlbach BK, Pohlman A, Van Cleve W, Hall JB,
Kress JP: Diagnostic utility of B-type natriuretic peptide in critically ill
patients with pulmonary edema: a prospective cohort study. Crit Care
2008, 12(1):R3.
20. Rana R, Vlahakis NE, Daniels CE, Jaffe AS, Klee GG, Hubmayr RD, Gajic O:
B-type natriuretic peptide in the assessment of acute lung injury and
cardiogenic pulmonary edema. Crit Care Med 2006, 34(7):1941–6.
21. Luyt CE, Combes A, Reynaud C, Hekimian G, Nieszkowska A, Tonnellier M,
Aubry A, Trouillet JL, Bernard M, Chastre J: Usefulness of procalcitonin for
the diagnosis of ventilator-associated pneumonia. Intensive Care Med
2008, 34(8):1434–40.
22. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A:
Inflammatory cytokines in the BAL of patients with ARDS. Persistent
elevation over time predicts poor outcome. Chest 1995, 108(5):1303–14.
23. Fujishima S, Sasaki J, Shinozawa Y, Takuma K, Hori S, Aikawa N: Interleukin
8 in ARDS. Lancet 1993, 342(8865):237–8.
24. Agrawal A, Zhuo H, Brady S, Levitt J, Steingrub J, Siegel MD, Soto G,
Peterson MW, Chesnutt MS, Matthay MA, Liu KD: Pathogenetic and
predictive value of biomarkers in patients with ALI and lower severity of
illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol
2012, 303(8):L634–9.
25. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT,
Matthay MA, National Heart Blood, and Lung Institute Acute Respiratory
Distress Syndrome Network: Use of risk reclassification with multiple
biomarkers improves mortality prediction in acute lung injury.
Crit Care Med 2011, 39(4):711–7.
26. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT,
Brower RG, Standiford TJ, Martin TR, Matthay MA, Network NACT:
Prognostic and pathogenetic value of combining clinical and
biochemical indices in patients with acute lung injury. Chest 2010,
137(2):288–96.
27. Koh H, Tasaka S, Hasegawa N, Asano K, Kotani T, Morisaki H, Takeda J,
Fujishima S, Matsuda T, Hashimoto S, Ishizaka A: Vascular endothelial
growth factor in epithelial lining fluid of patients with acute respiratory
distress syndrome. Respirology 2008, 13(2):281–4.
28. Stern JB, Fierobe L, Paugam C, Rolland C, Dehoux M, Petiet A, Dombret MC,
Mantz J, Aubier M, Crestani B: Keratinocyte growth factor and hepatocyte
growth factor in bronchoalveolar lavage fluid in acute respiratory
distress syndrome patients. Crit Care Med 2000, 28(7):2326–33.
29. Clark BJ, Bull TM, Benson AB, Stream AR, Macht M, Gaydos J, Meadows C,
Burnham EL, Moss M, the ANI: Growth differentiation factor-15 and
prognosis in acute respiratory distress syndrome: a retrospective cohort
study. Crit Care 2013, 17(3):R92.30. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, Cortez A,
Abbott J, Liu KD, Calfee CS: Plasma angiopoietin-2 predicts the onset of
acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013,
187(7):736–42.
31. Fujishima S, Morisaki H, Ishizaka A, Kotake Y, Miyaki M, Yoh K, Sekine K,
Sasaki J, Tasaka S, Hasegawa N, Kawai Y, Takeda J, Aikawa N: Neutrophil
elastase and systemic inflammatory response syndrome in the initiation
and development of acute lung injury among critically ill patients.
Biomed Pharmacother 2008, 62(5):333–8.
32. Yu S, Christiani DC, Thompson BT, Bajwa EK, Gong MN: Role of diabetes in
the development of acute respiratory distress syndrome*. Crit Care Med
2013, 41(12):2720–32.
33. Honiden S, Gong MN: Diabetes, insulin, and development of acute lung
injury. Crit Care Med 2009, 37(8):2455–64.
34. Jain M, Budinger GR, Lo A, Urich D, Rivera SE, Ghosh AK, Gonzalez A,
Chiarella SE, Marks K, Donnelly HK, Soberanes S, Varga J, Radigan KA,
Chandel NS, Mutlu GM: Leptin promotes fibroproliferative acute
respiratory distress syndrome by inhibiting peroxisome proliferator-
activated receptor-{gamma}. Am J Respir Crit Care Med 2011,
183(11):1490–8.
35. Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer
EM, Krautgartner WD, Stoiber W, Belohradsky BH, Rieber N, Kormann M,
Koller B, Roscher A, Roos D, Griese M, Eickelberg O, Doring G, Mall MA,
Hartl D: CXCR2 mediates NADPH oxidase-independent neutrophil
extracellular trap formation in cystic fibrosis airway inflammation.
Nature Med 2010, 16(9):1018–23.
36. Joyner BL, Jones SW, Cairns BA, Harris BD, Coverstone AM, Abode KA,
Ortiz-Pujols SM, Kocis KC, Noah TL: DNA and inflammatory mediators in
bronchoalveolar lavage fluid from children with acute inhalational
injuries. J Burn Care Res 2013, 34(3):326–33.
37. Calfee CS, Eisner MD, Parsons PE, Thompson BT, Conner ER Jr, Matthay MA,
Ware LB, Network NARDSCT: Soluble intercellular adhesion molecule-1
and clinical outcomes in patients with acute lung injury. Intensive Care
Med 2009, 35(2):248–57.
38. Sakamaki F, Ishizaka A, Handa M, Fujishima S, Urano T, Sayama K, Nakamura
H, Kanazawa M, Kawashiro T, Katayama M: Soluble form of P-selectin in
plasma is elevated in acute lung injury. Am J Respir Crit Care Med 1995,
151(6):1821–6.
39. Bersten AD, Hunt T, Nicholas TE, Doyle IR: Elevated plasma surfactant
protein-B predicts development of acute respiratory distress syndrome
in patients with acute respiratory failure. Am J Respir Crit Care Med 2001,
164(4):648–52.
40. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K, Acute Respiratory
Distress Syndrome Network: Plasma surfactant protein levels and clinical
outcomes in patients with acute lung injury. Thorax 2003, 58(11):983–8.
41. Lesur O, Langevin S, Berthiaume Y, Legare M, Skrobik Y, Bellemare JF, Levy
B, Fortier Y, Lauzier F, Bravo G, Nickmilder M, Rousseau E, Bernard A, Critical
Care Research Group of the Quebec Respiratory Health Network: Outcome
value of Clara cell protein in serum of patients with acute respiratory
distress syndrome. Intensive Care Med 2006, 32(8):1167–74.
42. Katayama M, Ishizaka A, Sakamoto M, Fujishima S, Sekiguchi K, Asano K,
Betsuyaku T, Kotani T, Ware LB, Matthay MA, Hashimoto S: Laminin
gamma2 fragments are increased in the circulation of patients with
early phase acute lung injury. Intensive Care Med 2010, 36(3):479–86.
43. Terpstra ML, Aman J, Van Nieuw Amerongen GP, Groeneveld AB: Plasma
biomarkers for acute respiratory distress syndrome: a systematic review
and meta-analysis. Crit Care Med 2014, 42(3):691–700.
doi:10.1186/2052-0492-2-32
Cite this article as: Fujishima: Pathophysiology and biomarkers of acute
respiratory distress syndrome. Journal of Intensive Care 2014 2:32.
